Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated™ Human Glucocerebrosidase (GA-GCB, Velaglucerase Alfa) ERT in Newly Diagnosed or Previously Treated (With Imiglucerase) Patients With Type 1 Gaucher Disease

NCT00954460 is registered in ClinicalTrials.gov with Shire as lead sponsor.

NCT NCT00954460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00954460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter Open-Label Treatment Protocol to Observe the Safety of Gene-Activated™ Human Glucocerebrosidase (GA-GCB, Velaglucerase Alfa) ERT in Newly Diagnosed or Previously Treated (With Imiglucerase) Patients With Type 1 Gaucher Disease
Lead sponsor
Shire
Phase
Expanded access
Overall status
Approved for marketing
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
32

Conditions

As the registry lists them; a condition with its own page is linked.

gaucher disease, type 1